A string of blunders led to the value of Novo Nordisk dropping £52bn last week. Could a new weight-loss pill help it regain its crown?
A string of blunders led to the value of Novo Nordisk dropping £52bn last week. Could a new weight-loss pill help it regain its crown?
Copy link
Novo Nordisk cuts its forecasts after a boom in copycats and the rise of Mounjaro
The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed its…
"I’m sure someone’s lost their job," said the CEO of Sandoz, which has now filed to launch a generic GLP-1 in Canada next year.
Report dashes hopes for new use for blockbuster weight-loss drug
The stock of the Wegovy and Ozempic maker is down nearly 50% year to date.
Novo Nordisk stock just had its worst day since Black Monday, after the maker of Ozempic and Wegovy slashed its 2025 outlook.
